1 School of Biosciences and Veterinary Medicine, University of Camerino, Via Circonvallazione 93/95, 62024 Matelica, Italy.
2 College of Veterinary Medicine, Iowa State University, 1800 Christensen Drive, Ames, IA 50011-1134, USA.
Benef Microbes. 2018 Jan 29;9(1):101-110. doi: 10.3920/BM2017.0023. Epub 2017 Oct 25.
Chronic constipation (CC) and idiopathic megacolon (IMC) occur frequently in cats. The aim of the study was to investigate the effects of a multi-strain probiotic (SLAB51™) in constipated cats (n=7) and in patients with megacolon and constipation (n=3). Ten pet cats with a diagnosis of chronic constipation, non-responsive to medical management received orally 2×10 bacteria daily for 90 days. For microbiota analysis, selected bacterial groups were analysed by qPCR. Histological samples in megacolons were evaluated for interstitial cells of Cajal (ICC), enteric neurons, and neuronal apoptosis. Biopsies were compared at baseline (T0) and after the end of treatment (T1), and with those obtained from healthy control tissues (archived material from five healthy cats). Constipated cats displayed significantly lower ICC, and cats with idiopathic megacolon had significantly more apoptotic enteric neurons than controls. After treatment with SLAB51™, significant decreases were observed for feline chronic enteropathy activity index (FCEAI) (P=0.006), faecal consistency score, and mucosal histology scores (P<0.001). In contrast, a significant increase of ICC was observed after probiotic therapy. Lactobacillus spp. and Bacteroidetes were increased significantly after treatment (comparing constipated cats before and after treatment, and control healthy cats to constipated cats after treatment), but no other differences in microbiota were found between healthy controls and constipated cats. Treatment with SLAB51™ in cats with chronic constipation and idiopathic megacolon showed significant clinical improvement after treatment, and histological parameters suggest a potential anti-inflammatory effect of SLAB51™, associated with a reduction of mucosal infiltration, and restoration of the number of interstitial cells of Cajal.
慢性便秘(CC)和特发性巨结肠(IMC)在猫中经常发生。本研究的目的是研究多菌株益生菌(SLAB51™)对便秘猫(n=7)和巨结肠伴便秘患者(n=3)的影响。10 只被诊断为慢性便秘的宠物猫,对药物治疗无反应,每天口服 2×10 细菌,持续 90 天。为了进行微生物组分析,通过 qPCR 分析了选定的细菌群。巨结肠的组织样本用于分析 Cajal 间质细胞(ICC)、肠神经元和神经元凋亡。在基线(T0)和治疗结束时(T1)与健康对照组组织(来自五只健康猫的存档材料)进行活检比较。便秘猫的 ICC 明显较低,特发性巨结肠猫的凋亡肠神经元明显多于对照组。在用 SLAB51™治疗后,猫慢性肠病活动指数(FCEAI)(P=0.006)、粪便稠度评分和黏膜组织学评分显著降低(P<0.001)。相反,在用益生菌治疗后,ICC 显著增加。治疗后,乳杆菌属和拟杆菌门的数量显著增加(与治疗前后的便秘猫以及治疗后的健康对照组猫相比),但在健康对照组和便秘猫之间未发现其他微生物组差异。在慢性便秘和特发性巨结肠的猫中用 SLAB51™治疗后,治疗后临床显著改善,组织学参数提示 SLAB51™具有潜在的抗炎作用,与减少黏膜浸润和 Cajal 间质细胞数量的恢复有关。